Pegasys: Uses, Dosage & Side Effects
Pegylated interferon alfa-2a – a once-weekly subcutaneous injection used in the treatment of chronic hepatitis B and chronic hepatitis C
Pegasys is the brand name for peginterferon alfa-2a, a long-acting pegylated form of recombinant human interferon alfa-2a. Interferons are naturally occurring proteins made by the immune system that help the body fight viruses, regulate cell growth and activate immune cells. In Pegasys, a 40-kilodalton branched polyethylene glycol (PEG) chain is attached to the interferon molecule, which increases the drug’s size, protects it from rapid breakdown and slows renal clearance. This allows Pegasys to be given as a single subcutaneous injection once a week, producing steadier drug levels and a more favourable efficacy profile than conventional interferon. Pegasys is authorised for the treatment of chronic hepatitis B in adults and children aged 3 years and over, and chronic hepatitis C in adults and children aged 5 years and over. In hepatitis C it is usually combined with ribavirin or, in the past, with direct-acting antivirals. It is a specialist prescription medicine, started and monitored by a hepatologist or infectious disease specialist.
Quick Facts: Pegasys
Key Takeaways
- Pegasys (peginterferon alfa-2a) is a long-acting pegylated interferon that harnesses the immune system to suppress hepatitis B and hepatitis C viruses, rather than killing the viruses directly like modern direct-acting antivirals.
- It is given as a once-weekly subcutaneous injection, usually at a dose of 180 micrograms, with a total treatment duration of 48 weeks for most hepatitis B and hepatitis C indications.
- The most common side effects are flu-like symptoms (fever, chills, fatigue, muscle pain), headache, loss of appetite, injection site reactions, hair thinning, mood changes and reduced blood cell counts; most can be managed with dose adjustment and supportive care.
- Pegasys must not be used in autoimmune hepatitis, decompensated cirrhosis (Child-Pugh B or C with features of liver failure), severe active depression or other severe psychiatric disease, and combination with ribavirin is contraindicated in pregnancy.
- In chronic hepatitis B, Pegasys offers the only licensed therapy that provides a finite 48-week course with a realistic chance of sustained off-treatment response and HBsAg loss (“functional cure”), making it an important option in selected HBeAg-positive and HBeAg-negative patients.
What Is Pegasys and What Is It Used For?
Pegasys is the brand name for peginterferon alfa-2a, a biological medicine that belongs to a class of drugs called pegylated interferons. Interferons are natural signalling proteins (cytokines) produced by the body in response to viral infections, cancer cells and other immune triggers. When interferons bind to receptors on the surface of cells, they switch on hundreds of genes that produce antiviral enzymes, stop cells from dividing, and help immune cells such as natural killer (NK) cells and T-lymphocytes recognise and destroy infected cells. Recombinant interferon alfa-2a, produced in genetically engineered Escherichia coli bacteria, has been used in medicine for more than 30 years as an antiviral and antitumour drug.
What makes Pegasys distinct from older interferon products such as Roferon-A is the attachment of a large, branched molecule of polyethylene glycol (PEG) to the interferon. This process, called pegylation, effectively doubles the weight of the molecule and creates a hydrophilic shell around it. The consequences are profound: renal filtration is slowed dramatically, proteolytic enzymes cannot easily degrade the molecule, and antibodies find it harder to recognise. The result is a tenfold to fortyfold increase in the circulating half-life, rising from about 3 to 4 hours for non-pegylated interferon alfa-2a to approximately 160 hours for Pegasys. This allows once-weekly dosing, produces far more stable plasma concentrations, and improves antiviral efficacy in chronic viral hepatitis.
At the molecular level, Pegasys binds to the type I interferon receptor (IFNAR), a two-subunit receptor (IFNAR1 and IFNAR2) expressed on almost every cell in the body. Receptor engagement activates the JAK-STAT (Janus kinase – signal transducer and activator of transcription) signalling pathway, leading to phosphorylation of STAT1 and STAT2, formation of the ISGF3 transcription factor complex, and induction of a broad portfolio of interferon-stimulated genes (ISGs) such as MxA, OAS, PKR and ISG15. These gene products inhibit viral transcription and translation, degrade viral RNA, and make infected cells less hospitable hosts. At the same time, Pegasys upregulates major histocompatibility complex (MHC) class I molecules, activates dendritic cells and shifts the immune response towards a Th1 profile, enhancing cell-mediated clearance of virus-infected hepatocytes.
Pegasys is authorised by the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), and many other regulatory authorities worldwide. It received its first EU marketing authorisation in 2002 and remains on the World Health Organization (WHO) Model List of Essential Medicines. The approved indications are:
Chronic Hepatitis B in Adults
Pegasys is indicated for the treatment of adult patients with HBeAg-positive or HBeAg-negative chronic hepatitis B who have compensated liver disease and evidence of viral replication, raised alanine aminotransferase (ALT) levels, and histologically verified liver inflammation and/or fibrosis. The pivotal trial by Marcellin and colleagues (New England Journal of Medicine, 2004) randomised 814 HBeAg-positive patients to Pegasys monotherapy, lamivudine monotherapy, or the combination. At 24 weeks after the end of a 48-week treatment course, HBeAg seroconversion was 32% with Pegasys versus 19% with lamivudine, and HBsAg seroconversion was 3% – rates never previously achieved with nucleos(t)ide analogues alone. Similar benefits were shown in HBeAg-negative patients. Pegasys therefore remains the only therapy offering a realistic chance of off-treatment sustained response and functional cure in chronic hepatitis B.
Chronic Hepatitis C in Adults
Pegasys is indicated for the treatment of adult patients with chronic hepatitis C, either as monotherapy (if ribavirin is contraindicated) or, historically, in combination with ribavirin. The landmark phase III trial by Fried and colleagues (New England Journal of Medicine, 2002) compared Pegasys plus ribavirin with conventional interferon alfa-2b plus ribavirin in 1,121 patients and demonstrated a significantly higher sustained virological response (SVR) rate of 56% versus 44%. With the advent of interferon-free regimens based on direct-acting antivirals (DAAs) such as sofosbuvir/velpatasvir and glecaprevir/pibrentasvir, SVR rates now exceed 95% in 8 to 12 weeks without injections. Current international guidelines therefore recommend DAA-based regimens as first-line therapy, with interferon-based therapy reserved for rare situations or resource-limited settings.
Paediatric Use
Pegasys is authorised in children aged 3 years and older with chronic hepatitis B, and in children aged 5 years and older with chronic hepatitis C (in combination with ribavirin). Paediatric dosing is based on body surface area. The decision to treat children is complex because interferon therapy can slow weight gain and linear growth; treatment is usually reserved for children with active liver disease in whom the benefits of a finite course outweigh the risks of delaying therapy until adulthood.
Before pegylation, standard interferon had to be given three times a week, produced sharp peaks and troughs in plasma levels, and was associated with severe flu-like symptoms around each injection. Pegylation – by adding a 40-kilodalton branched PEG polymer to the interferon protein – creates a molecule large enough to avoid renal filtration but small enough to reach the liver and immune cells. The 160-hour half-life allows once-weekly dosing, smoother pharmacokinetics, and substantially higher sustained virological response rates in chronic hepatitis than the original non-pegylated product.
What Should You Know Before Taking Pegasys?
Contraindications
There are several situations in which Pegasys must not be used. Your doctor will review your full medical history, a physical examination and baseline laboratory tests before starting therapy to ensure that none of these apply to you.
- Hypersensitivity: Do not use Pegasys if you have a known allergy to any alpha interferon, to peginterferon alfa-2a itself, to Escherichia coli-derived products, or to any of the excipients such as benzyl alcohol.
- Autoimmune hepatitis: Interferons can trigger or worsen autoimmune reactions. Pegasys is contraindicated in patients with autoimmune hepatitis because it may cause severe, sometimes life-threatening flares.
- Decompensated liver disease: Pegasys is contraindicated in patients with severe hepatic dysfunction or decompensated cirrhosis (Child-Pugh class B or C with features such as ascites, variceal bleeding, encephalopathy or jaundice) because the risk of hepatic failure and sepsis outweighs any benefit.
- Co-infection with HIV in decompensated cirrhosis: Pegasys is contraindicated in patients with HIV/HCV co-infection who have cirrhosis and a Child-Pugh score of 6 or more, unless solely due to indirect hyperbilirubinaemia from atazanavir or indinavir.
- Severe psychiatric disease: Pegasys is contraindicated in patients with a history of severe psychiatric disease, particularly severe depression, suicidal ideation or suicide attempts.
- Severe bone marrow suppression: Treatment must not be initiated in patients with severe pre-existing neutropenia (<1,500 cells/mm³), thrombocytopenia (<90,000/mm³) or anaemia.
- Neonates and infants under 3 years: Pegasys must not be used in children under 3 years because of the benzyl alcohol excipient, which may cause fatal “gasping syndrome” in young infants.
- Combination with telbivudine: Co-administration of Pegasys with telbivudine is contraindicated because of a markedly increased risk of peripheral neuropathy.
Warnings and Precautions
Pegasys can cause or worsen depression, anxiety, irritability, aggression and, in rare cases, suicidal thoughts, suicide attempts or completed suicide. These risks are highest in patients with a prior history of psychiatric illness but can also occur in patients with no previous psychiatric history. Your doctor will screen you for depression before, during and after treatment. Stop treatment and seek urgent medical help if you or those around you notice significant changes in mood, behaviour, hopelessness or thoughts of self-harm.
Tell your doctor before starting Pegasys if any of the following apply to you:
- Depression or psychiatric history: Interferon can unmask or worsen depression, anxiety and psychotic symptoms. A thorough psychiatric assessment is required before and during treatment.
- Thyroid disorders: Pegasys can induce hypothyroidism, hyperthyroidism or autoimmune thyroiditis. Baseline and periodic thyroid-stimulating hormone (TSH) and free T4 measurements are standard.
- Cardiovascular disease: Patients with pre-existing cardiac disease, hypertension, arrhythmias or a history of myocardial infarction may be at greater risk of cardiovascular events during therapy. A baseline ECG is recommended.
- Diabetes and impaired glucose tolerance: Pegasys may precipitate or worsen type 1 diabetes mellitus and hyperglycaemia. Glucose monitoring is required throughout therapy.
- Autoimmune disorders: Pegasys can trigger or exacerbate autoimmune disease, including autoimmune thyroid disease, rheumatoid arthritis, systemic lupus erythematosus, psoriasis, sarcoidosis and type 1 diabetes.
- Pulmonary disorders: Cases of pulmonary infiltrates, pneumonitis, interstitial lung disease and pulmonary hypertension have been reported. Tell your doctor if you develop persistent cough or shortness of breath.
- Ophthalmologic disorders: Rare cases of retinopathy, retinal haemorrhage, optic neuritis and retinal artery or vein occlusion have been described. A baseline eye examination is recommended, particularly in patients with diabetes or hypertension.
- Infections: Pegasys suppresses bone marrow and can increase the risk of serious bacterial, viral and fungal infections. Interrupt therapy promptly if severe infection develops.
- HIV/HCV co-infection with highly active antiretroviral therapy (HAART): There is a risk of lactic acidosis, hepatic decompensation and severe cytopenias. Close monitoring is required.
During treatment, contact your doctor immediately if you experience any of the following:
- Persistent fever, chills, sore throat, severe mouth ulcers or unusual bleeding or bruising (signs of bone marrow suppression or infection)
- Persistent or worsening depression, anxiety, hopelessness or any thoughts of self-harm
- New chest pain, palpitations, shortness of breath or swelling of the legs
- Yellowing of the skin or eyes, dark urine, pale stools or severe abdominal pain
- New or worsening changes in vision, blurred vision, blind spots, eye pain or vision loss
- New numbness, tingling or weakness in the arms or legs
- Severe skin reactions with blistering, widespread rash or skin peeling
Pregnancy and Breastfeeding
Pegasys must only be used in women of childbearing potential if they are using effective contraception during treatment. In animal studies, interferons have caused abortifacient effects, and data in pregnant women are limited. If Pegasys is used alone, the decision should weigh the potential benefits against the risk to the fetus, and treatment is generally postponed until after pregnancy unless there is an urgent clinical indication.
When Pegasys is combined with ribavirin, as in historical regimens for chronic hepatitis C, the combination is strictly contraindicated in pregnant women because ribavirin is a proven teratogen that causes serious birth defects and fetal death. Women of childbearing potential and their male partners must use two reliable forms of contraception during treatment and for at least 6 months after the last dose of ribavirin (4 months in some product labels for male patients). A pregnancy test must be negative before starting therapy and is repeated monthly during treatment. If pregnancy occurs during therapy or in the 6 months after, the case should be reported to the Ribavirin Pregnancy Registry.
It is not known whether peginterferon alfa-2a is excreted in human breast milk. Because of the theoretical risk of serious adverse reactions in nursing infants, the decision to continue breastfeeding or to continue Pegasys should weigh the importance of the drug to the mother. Usually, breastfeeding is not recommended during Pegasys therapy.
Children and Adolescents
Pegasys is authorised in children aged 3 years and older for chronic hepatitis B and 5 years and older for chronic hepatitis C (in combination with ribavirin). Growth monitoring is essential during treatment because interferon has been associated with a temporary reduction in growth velocity and weight gain. Puberty should be assessed before starting therapy. In younger children, the risk-benefit balance and the availability of alternative therapies must be carefully considered.
Driving and Operating Machinery
Pegasys can cause fatigue, dizziness, confusion, drowsiness and visual disturbances. Patients who experience these effects should not drive a car, ride a bicycle or operate machinery. Flu-like symptoms after the weekly injection may be particularly pronounced in the first few weeks of therapy.
Important Information About Ingredients
Pegasys solution for injection contains benzyl alcohol as a preservative (10 mg per 1 ml). Benzyl alcohol may cause allergic reactions and must not be given to premature babies or neonates, and should be avoided in young children under 3 years of age. Pegasys also contains sodium acetate, sodium chloride, polysorbate 80 and water for injection. Each dose contains less than 1 mmol (23 mg) of sodium, so it is essentially “sodium-free” for patients on low-sodium diets.
How Does Pegasys Interact with Other Drugs?
Pegasys has a complex interaction profile that reflects its immunomodulatory mechanism and its effect on hepatic drug-metabolising enzymes. Unlike many small-molecule drugs, it is not itself metabolised by cytochrome P450 enzymes, but it can modify their activity. The most clinically important interaction is inhibition of cytochrome P450 1A2 (CYP1A2), which can raise plasma levels of theophylline and other CYP1A2 substrates. Pegasys can also alter the pharmacokinetics of methadone, most likely through a combination of CYP-mediated and immunomodulatory mechanisms.
Because Pegasys affects the immune system and the bone marrow, it may also interact pharmacodynamically with other drugs that suppress bone marrow (such as zidovudine or azathioprine), cause neuropathy (such as telbivudine), or trigger autoimmune reactions. In hepatitis C combination regimens, the interaction profile of ribavirin or direct-acting antivirals must also be considered. Always tell your doctor, pharmacist or nurse about every prescription medicine, over-the-counter product, vitamin or herbal remedy you use.
Major Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Telbivudine (HBV nucleoside analogue) | Markedly increased risk of peripheral neuropathy when combined with Pegasys | Combination is contraindicated |
| Theophylline and other CYP1A2 substrates | Pegasys inhibits CYP1A2, raising theophylline concentrations and the risk of toxicity (nausea, arrhythmia, seizures) | Monitor theophylline levels; dose reduction usually required during Pegasys therapy |
| Methadone | Pegasys may increase methadone AUC by approximately 10–15%; signs of opioid toxicity (respiratory depression, sedation, QT prolongation) can occur | Use with caution, especially at high methadone doses; monitor for opioid side effects |
| Ribavirin (antiviral, used with Pegasys for HCV) | Additive haemolytic anaemia and leukopenia; teratogenic in pregnancy | Required combination in many HCV regimens but not in pregnancy; regular haemoglobin monitoring and contraception mandatory |
| Didanosine (HIV nucleoside analogue) | Increased risk of mitochondrial toxicity, lactic acidosis, pancreatitis and hepatic decompensation in HIV/HCV co-infection | Avoid combination; switch to an alternative nucleoside reverse transcriptase inhibitor |
| Zidovudine (HIV nucleoside analogue) | Increased risk of severe anaemia and neutropenia when combined with Pegasys and ribavirin | Avoid if possible; consider alternative antiretroviral regimens |
| Azathioprine | Additive myelosuppression; severe pancytopenia has been reported | Avoid concurrent use where possible; if combination is necessary, monitor blood counts very closely |
Minor Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Stavudine (HIV nucleoside analogue) | Possible increase in mitochondrial toxicity and lipoatrophy in HIV/HCV co-infected patients | Combination should be avoided where alternatives are available |
| Direct-acting antivirals for HCV (e.g. sofosbuvir, simeprevir) | Historically combined with Pegasys and ribavirin before interferon-free regimens | Current guidelines rarely recommend adding Pegasys to modern DAAs; specialist decision required |
| Mycophenolate mofetil and other immunosuppressants | Interferons may oppose the effect of immunosuppression and risk graft rejection in transplant patients | Generally avoid Pegasys in organ transplant recipients |
| Live vaccines (e.g. MMR, varicella, yellow fever) | Potentially reduced efficacy and increased risk of vaccine-associated disease during immunomodulation | Avoid live vaccines during and shortly after Pegasys therapy; use inactivated vaccines where possible |
| Warfarin and other coumarin anticoagulants | Changes in hepatic function and CYP activity may alter INR control | Monitor INR more frequently when starting, stopping or adjusting Pegasys therapy |
Interferons may also alter the clearance of drugs metabolised by CYP2D6 and CYP2C9 to a lesser extent. If you take medicines for epilepsy, depression, cardiac arrhythmia or immunosuppression, your doctor will consider whether dose adjustments are needed during and after Pegasys therapy. Always provide a complete list of your current medicines at every clinic visit.
What Is the Correct Dosage of Pegasys?
Pegasys is always prescribed and monitored by a physician experienced in the treatment of chronic hepatitis. The dose, treatment duration and dose adjustments are individualised based on the indication, patient weight, renal and hepatic function, co-infections, and tolerability. The injection is usually given into the subcutaneous fat of the abdomen or the front of the thigh, with injection sites rotated each week to reduce the risk of local skin reactions.
Chronic Hepatitis B (Adults)
Pegasys for HBeAg-positive and HBeAg-negative Chronic Hepatitis B
Dose: 180 micrograms subcutaneously once weekly
Duration: 48 weeks
Monitoring: Baseline liver function tests, HBV DNA, HBeAg/anti-HBe, HBsAg, TSH, full blood count; repeat regularly during therapy and for at least 24 weeks post-treatment
Response is defined by HBeAg seroconversion (for HBeAg-positive patients), HBV DNA suppression, and ideally HBsAg loss (functional cure). Treatment is given as a finite 48-week course without a planned extension.
Chronic Hepatitis C (Adults)
Pegasys + Ribavirin for Chronic Hepatitis C
Dose: Pegasys 180 micrograms subcutaneously once weekly, combined with oral ribavirin (dose based on weight and HCV genotype, typically 1000–1200 mg/day divided twice daily)
Duration: 48 weeks for genotype 1 and 4; 24 weeks for genotype 2 and 3 (older regimen). Shorter durations have been used with early viral response.
Monotherapy: Pegasys 180 µg weekly for 48 weeks, used only when ribavirin is contraindicated.
Status today: Interferon-free DAA regimens have replaced Pegasys-based therapy in almost all first-line settings. Pegasys is retained only for highly selected cases or resource-limited settings.
Children and Adolescents
Paediatric Dosing (Chronic Hepatitis B & C)
Dose: Based on body surface area (BSA): 180 µg/1.73 m² subcutaneously once weekly
Duration: 48 weeks for chronic hepatitis B (HBeAg-positive); up to 48 weeks for chronic hepatitis C, with ribavirin added for children aged 5 years and over
Special considerations: Careful monitoring of growth, weight, puberty and thyroid function is required. Maximum dose is 180 micrograms weekly.
Dose Adjustments
Dose adjustments are common and form part of the standard management of Pegasys therapy. Adjustments are based primarily on blood counts and tolerability:
- Neutropenia: If the absolute neutrophil count (ANC) falls below 750/mm³, reduce Pegasys to 135 µg weekly. If ANC falls below 500/mm³, withhold Pegasys until ANC returns above 1,000/mm³, then restart at 90 µg weekly and increase as tolerated.
- Thrombocytopenia: If the platelet count falls below 50,000/mm³, reduce Pegasys to 90 µg weekly. If platelets fall below 25,000/mm³, discontinue Pegasys.
- Depression: For mild depression, increase clinical review. For moderate depression, reduce Pegasys to 135–90 µg weekly and start antidepressants. For severe depression or suicidal ideation, stop Pegasys immediately and refer to psychiatry.
- Hepatic dysfunction: ALT flares are expected in chronic hepatitis B during treatment and often indicate immune-mediated clearance of infected hepatocytes. Progressive rises require dose reduction or discontinuation, especially if bilirubin is rising.
- Thyroid dysfunction: Adjust thyroid replacement or antithyroid therapy as needed, but interferon therapy can usually be continued.
- Renal impairment: In patients with end-stage renal disease on haemodialysis, reduce Pegasys to 135 µg weekly.
- Hepatic impairment: In compensated cirrhosis, no routine dose adjustment is required, but patients must be closely monitored for signs of decompensation.
Missed Dose
If you miss a scheduled injection and remember within 1 to 2 days, give the dose as soon as possible and continue with the next dose on your usual weekly schedule. If more than 2 days have passed, take the next dose on the originally scheduled day and do not double up. Ask your doctor or pharmacist for advice if more than a week passes between injections. Do not discontinue Pegasys on your own without medical advice, as this can result in loss of treatment benefit.
Overdose
Experience with overdose is limited. Accidental double dosing has been reported without serious harm in most cases. Reported effects of overdose include intensified flu-like symptoms, fatigue, nausea, neutropenia and transaminase elevations. There is no specific antidote; treatment is supportive and symptomatic. If you suspect an overdose of Pegasys, contact your doctor, a poison centre or your nearest emergency department immediately.
How Pegasys Is Given
Pegasys is supplied in either pre-filled syringes or pre-filled autoinjector pens (ProClick). Most patients are taught to self-inject at home after initial training by a nurse. The injection is given subcutaneously into the abdominal wall (at least 5 cm away from the navel) or the front of the thigh. Site rotation each week reduces skin irritation. The solution must be inspected for particles and discolouration before use and should not be shaken.
The injection is usually given in the evening, which helps many patients sleep through the most intense flu-like symptoms that often follow in the first 6 to 24 hours. Paracetamol (acetaminophen) taken just before or immediately after the injection, and again every 6 hours for the first 24 hours, can substantially reduce the severity of these symptoms. Good hydration also helps.
Pegasys should always be prescribed and managed by a physician experienced in chronic hepatitis – usually a hepatologist, gastroenterologist or infectious disease specialist. Dose, duration and monitoring are individualised and require laboratory and clinical follow-up every 2 to 4 weeks during the first months of therapy.
What Are the Side Effects of Pegasys?
Almost all patients experience at least some side effects during Pegasys therapy. Flu-like symptoms are expected and usually most pronounced during the first 2 to 4 weeks, improving over time. Psychological and haematological side effects, by contrast, may develop later in therapy and require continuous monitoring. With good supportive care, most patients complete a full 48-week course, and most side effects resolve after treatment ends.
The side effects listed below are organised by frequency category as reported in clinical trials and the Summary of Product Characteristics. Frequencies are based on the cumulative clinical experience with Pegasys monotherapy and in combination with ribavirin.
Very Common
May affect more than 1 in 10 people
- Flu-like symptoms: fever, chills, shivering
- Headache
- Fatigue, weakness (asthenia)
- Muscle pain (myalgia), joint pain (arthralgia)
- Injection site reactions (pain, redness, swelling, itching)
- Loss of appetite, weight loss
- Nausea, abdominal pain, diarrhoea
- Hair thinning or hair loss (alopecia)
- Dry skin, itching (pruritus), skin rash, dermatitis
- Insomnia, sleep disturbance
- Depression, anxiety, irritability, mood swings, concentration difficulty
- Dizziness, memory disturbance
- Dyspnoea, cough
- Dry mouth, taste disturbance
- Low white blood cell count (neutropenia, leukopenia, lymphopenia)
- Low platelet count (thrombocytopenia)
- Anaemia (particularly with ribavirin combination)
- Elevated liver enzymes (ALT/AST flare is expected in HBV)
Common
May affect up to 1 in 10 people
- Hypothyroidism, hyperthyroidism, autoimmune thyroiditis
- Diabetes mellitus, hyperglycaemia
- Upper respiratory tract infection, bronchitis, oral candidiasis, herpes simplex reactivation, pharyngitis, sinusitis
- Cold sores (herpes labialis), fungal skin infections
- Migraine
- Tinnitus, vertigo, earache
- Palpitations, tachycardia, peripheral oedema
- Flushing
- Dyspnoea on exertion, epistaxis (nosebleeds), nasopharyngitis, throat or chest pain
- Vomiting, dyspepsia, dysphagia, mouth ulcers, gum bleeding, gastritis, constipation
- Psoriasis, urticaria, eczema, increased sweating, night sweats, photosensitivity
- Back pain, muscle cramps, bone pain, neck pain, musculoskeletal pain
- Erectile dysfunction
- Blurred vision, eye pain, eye inflammation, dry eyes
- Faint (syncope), paraesthesia, hypoaesthesia, tremor, taste loss, nightmares, drowsiness
- Thirst
Uncommon
May affect up to 1 in 100 people
- Suicidal ideation, hallucinations, aggression
- Peripheral neuropathy
- Heart failure, cardiomyopathy, arrhythmia, atrial fibrillation, pericarditis, supraventricular tachycardia
- Hypertension
- Interstitial lung disease, pneumonitis, pulmonary embolism
- Gastrointestinal bleeding
- Liver dysfunction
- Dehydration
- Pneumonia, endocarditis, otitis externa, skin infection
- Hepatic tumour (benign)
- Hypersensitivity reactions
- Autoimmune disorders including systemic lupus erythematosus, rheumatoid arthritis, sarcoidosis
- Diabetic ketoacidosis
- Retinal haemorrhage, retinopathy, corneal ulcer
- Deafness
Rare
May affect up to 1 in 1,000 people
- Suicide, psychotic disorder
- Myocardial infarction, angina pectoris
- Coma, seizure, facial paralysis
- Thrombotic thrombocytopenic purpura
- Anaphylaxis
- Optic neuritis, papilloedema, retinal vascular disorders
- Pulmonary hypertension
- Pancreatitis
- Hepatic failure, cholangitis, fatty liver
- Myositis, rhabdomyolysis
- Interstitial nephritis, renal insufficiency, nephrotic syndrome
Very Rare
May affect up to 1 in 10,000 people
- Aplastic anaemia, pure red cell aplasia
- Idiopathic/thrombotic thrombocytopenic purpura
- Stevens-Johnson syndrome, toxic epidermal necrolysis
- Erythema multiforme
- Serous retinal detachment
Not Known
Frequency cannot be estimated from available data
- Vogt-Koyanagi-Harada disease (an autoimmune disorder affecting eyes, skin and nervous system)
- Ischaemic colitis, tongue pigmentation
- Mania and bipolar disorders
- Pulmonary arterial hypertension (HCV-related)
- Homicidal ideation
- Reactivation of hepatitis B in HBV/HCV co-infected patients after HCV cure
It is important to report any suspected side effects to your healthcare provider. Reporting helps regulatory authorities continuously monitor the benefit-risk balance of medicines. You can also report side effects directly to your national pharmacovigilance agency (e.g., the FDA MedWatch programme in the United States, the Yellow Card scheme in the United Kingdom, or the EMA EudraVigilance system in the European Union).
How Should Pegasys Be Stored?
Correct storage of Pegasys is critical because it is a protein biological that can be irreversibly damaged by heat, freezing and light. Most patients self-inject at home, so understanding storage at home and during travel is essential to maintain drug safety and efficacy.
- Refrigerate (2–8 °C): Store Pegasys in a refrigerator. Do not store the syringes or pens in the coldest part of the fridge (the back wall or near the freezer compartment). Keep them in the middle shelves or vegetable drawer where the temperature is most stable.
- Do not freeze: Never place Pegasys in a freezer. Freezing damages the interferon protein and the pegylation chain, destroying its activity. If accidentally frozen, discard the product.
- Protect from light: Always keep Pegasys in the original outer carton until immediately before use. Light exposure can degrade the active ingredient.
- Travel and short-term storage: If a refrigerator is not available (for example during travel), Pegasys may be kept at temperatures below 25 °C for up to 24 hours. After that period it must be used or discarded; it cannot be returned to the refrigerator for prolonged storage.
- Expiry date: Do not use after the expiry date (EXP) printed on the carton and syringe/pen. The expiry date refers to the last day of the stated month.
- Visual inspection: Before injecting, inspect the solution. It should be clear and colourless to slightly yellowish. Do not use if it contains particles, is discoloured, or if the packaging is damaged.
- Keep out of the sight and reach of children: Store the refrigerator compartment safely and always dispose of used needles in a puncture-proof sharps container.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures will help protect the environment and comply with local regulations for the disposal of biological medicinal products.
What Does Pegasys Contain?
Knowing exactly what Pegasys contains matters for identifying allergens, understanding its biological nature, and making informed decisions about its use.
- Active substance: Peginterferon alfa-2a, a recombinant human interferon alfa-2a molecule covalently conjugated to a 40-kilodalton branched methoxy polyethylene glycol chain (bis-monomethoxy polyethylene glycol).
- Strengths: 135 micrograms in 0.5 ml, and 180 micrograms in 0.5 ml, of solution for injection.
- Excipients: Sodium chloride (isotonicity), polysorbate 80 (surfactant), benzyl alcohol (preservative – 10 mg/ml), sodium acetate, acetic acid (pH buffer), and water for injection.
Appearance: Pegasys is a clear, colourless to slightly yellowish solution for injection. It is supplied in single-use pre-filled syringes with a detachable needle or as a pre-filled autoinjector pen (ProClick). Both delivery devices contain 0.5 ml of solution and are designed for subcutaneous injection.
Pack sizes: Cartons contain 1 or 4 pre-filled syringes or pens with accompanying alcohol swabs and safety accessories. Exact pack sizes and presentations may vary by country.
Marketing authorisation holder: Roche Registration GmbH, Emil-Barell-Strasse 1, 79639 Grenzach-Wyhlen, Germany (EU). In the United States, Pegasys is marketed by Genentech, a member of the Roche Group.
Other Brand Names
Pegasys is the global trade name used for peginterferon alfa-2a by Roche and Genentech. No approved biosimilar of peginterferon alfa-2a is currently authorised in the EU or US, although unbranded generic peginterferon alfa-2a products are available in some markets worldwide. Always check the brand name and leaflet of any product you receive, and note that peginterferon alfa-2a (Pegasys) is not interchangeable with peginterferon alfa-2b (PegIntron), peginterferon beta-1a (Plegridy) or other interferon products – each has a different molecular structure, dose and pharmacokinetic profile.
Frequently Asked Questions About Pegasys
Pegasys and PegIntron are both pegylated alpha interferons, but they are not interchangeable. Pegasys contains peginterferon alfa-2a, linked to a large 40-kilodalton branched PEG chain, and is given as a fixed 180 µg weekly dose. PegIntron contains peginterferon alfa-2b, linked to a smaller 12-kilodalton linear PEG chain, and is dosed according to body weight (typically 1.5 µg/kg weekly). The pharmacokinetics differ: Pegasys has a longer half-life and more stable plasma levels, whereas PegIntron has a shorter half-life and more tissue distribution. Clinical efficacy in chronic hepatitis C is broadly similar, and the choice between them is based on guidelines, availability, and patient factors.
Yes. Most adult patients self-inject Pegasys at home once a week after initial training by a specialist nurse. Pegasys is available either as a pre-filled syringe with a detachable needle or as a pre-filled autoinjector pen (ProClick), which many patients find easier to handle and less intimidating than a conventional syringe. The injection is given into the subcutaneous fat of the abdomen (at least 5 cm from the navel) or the front of the thigh. Rotating injection sites each week reduces the risk of skin irritation. Many patients inject in the evening to sleep through the flu-like symptoms that typically follow the first few doses. Used needles and syringes must go into a puncture-proof sharps container provided by your pharmacy or hospital.
Flu-like symptoms after Pegasys – fever, chills, headache, muscle and joint pain, fatigue – are very common, particularly in the first few weeks of therapy, and gradually improve with continued treatment. Practical measures include taking paracetamol (acetaminophen) at the standard adult dose of 500–1,000 mg 30 minutes before or immediately after the injection and repeating every 6 hours for the first 24 hours, drinking plenty of fluids, dressing warmly, and injecting in the evening so that symptoms peak overnight. Avoid non-steroidal anti-inflammatory drugs such as ibuprofen or naproxen in chronic hepatitis if you have advanced liver disease, as they can worsen platelet function. If symptoms remain severe or intolerable, tell your specialist team – dose adjustments and additional supportive care are possible.
Chronic hepatitis B is not yet fully curable because the virus hides in long-lived hepatocytes in the form of covalently closed circular DNA (cccDNA). However, Pegasys offers the best chance of a “functional cure”, defined as sustained loss of hepatitis B surface antigen (HBsAg) with or without anti-HBs seroconversion after stopping therapy. In HBeAg-positive chronic hepatitis B, approximately 30% of patients achieve HBeAg seroconversion and 3–11% lose HBsAg after 48 weeks of Pegasys. These response rates are higher than those achieved with short courses of nucleos(t)ide analogues alone. Response rates are particularly favourable in younger patients with low baseline HBV DNA levels and genotypes A and B. Lifelong cure is possible but not guaranteed, and follow-up monitoring continues for years.
For almost all patients with chronic hepatitis C today, the answer is no. Direct-acting antivirals (DAAs) such as sofosbuvir/velpatasvir, glecaprevir/pibrentasvir and elbasvir/grazoprevir achieve sustained virological response (cure) rates exceeding 95% in 8 to 12 weeks with minimal side effects and no injections. International guidelines (AASLD-IDSA, EASL, WHO) now recommend DAA-based regimens as first-line therapy for all HCV genotypes. Pegasys-based regimens are reserved for rare situations such as certain drug-resistant infections, contraindications to specific DAAs, or regions where DAAs are unavailable or unaffordable. If your physician is proposing interferon-based therapy today, ask whether a DAA regimen is suitable instead.
Monitoring is intensive, particularly in the first few months. Before starting therapy, your doctor will arrange baseline blood tests (full blood count, liver function, thyroid function, creatinine, glucose, autoantibodies), viral markers (HBV DNA or HCV RNA, HBeAg/anti-HBe, HBsAg), a pregnancy test if applicable, an eye examination if you have diabetes or hypertension, and an ECG if you have cardiac risk factors. During treatment, blood counts and liver tests are repeated every 2–4 weeks for the first 8 weeks, then every 4–8 weeks. Thyroid function is checked every 12 weeks. Psychiatric screening is performed at each visit. After completing therapy, monitoring continues for at least 24 weeks (and often several years) to assess sustained response and late relapse.
References
- European Medicines Agency (EMA). Pegasys – Summary of Product Characteristics (SmPC). Last updated 2025. Available at: ema.europa.eu/en/medicines/human/EPAR/pegasys
- U.S. Food and Drug Administration (FDA). Pegasys (peginterferon alfa-2a) – Prescribing Information. Last updated 2024.
- European Association for the Study of the Liver (EASL). EASL 2025 Clinical Practice Guidelines on the management of hepatitis B virus infection. Journal of Hepatology. 2025.
- European Association for the Study of the Liver (EASL). EASL recommendations on treatment of hepatitis C. Journal of Hepatology. 2024.
- American Association for the Study of Liver Diseases & Infectious Diseases Society of America (AASLD-IDSA). HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. 2025. Available at: hcvguidelines.org
- Marcellin P, Lau GKK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. New England Journal of Medicine. 2004;351(12):1206-1217. doi:10.1056/NEJMoa040431
- Lau GKK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. New England Journal of Medicine. 2005;352(26):2682-2695. doi:10.1056/NEJMoa043470
- Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine. 2002;347(13):975-982. doi:10.1056/NEJMoa020047
- Hadziyannis SJ, Sette H, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Annals of Internal Medicine. 2004;140(5):346-355. doi:10.7326/0003-4819-140-5-200403020-00010
- World Health Organization (WHO). Guidelines for the prevention, diagnosis, care and treatment of people with chronic hepatitis B infection. Geneva: World Health Organization; 2024.
- World Health Organization (WHO). Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Geneva: World Health Organization; 2022.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List, 2023. Geneva: World Health Organization.
Editorial Team
Medical Content
iMedic Medical Editorial Team – Specialists in Hepatology, Infectious Diseases and Clinical Pharmacology
Medical Review
iMedic Medical Review Board – Independent panel following WHO, EMA, FDA, EASL and AASLD-IDSA guidelines
Evidence Level
Level 1A – Based on systematic reviews, meta-analyses, and randomised controlled trials
Last Reviewed
– Updated according to current EMA SmPC, FDA prescribing information, EASL 2025 HBV guidelines and AASLD-IDSA HCV guidance
All medical content on iMedic is written and reviewed by qualified healthcare professionals following the GRADE evidence framework. We adhere to strict editorial standards with no commercial funding or pharmaceutical sponsorship. For questions or corrections, please contact our editorial team.